Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.

Cancer research - 15 Feb 2010

Marina Ovidiu, Hainz Ursula, Biernacki Melinda A, Zhang Wandi, Cai Ann, Duke-Cohan Jonathan S, Liu Fenglong, Brusic Vladimir, Neuberg Donna, Kutok Jeffery L, Alyea Edwin P, Canning Christine M, Soiffer Robert J, Ritz Jerome, Wu Catherine J

Abstract excerpt

Patients with chronic lymphocytic leukemia (CLL) who relapse after allogeneic transplant may achieve durable remission following donor lymphocyte infusion (DLI), showing the potency of donor-derived immunity in eradicating tumors. We sought to elucidate the antigenic basis of the effective graft-...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Surface
Share to B-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Marrow Transplantation

Share to Cell Lineage

Share to Immunity, Innate

Share to Immunodominant Epitopes

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Protein Array Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 20124481
DOI: 10.1158/0008-5472.CAN-09-3143
PMCID: PMC2852266

Genes

DAPK3
OGFOD1
ZFYVE19
SERBP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20124481-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.PMID 20124481Read ↗

Efficacious Immune Therapy in Chronic Myelogenous Leukemia (CML) Recognizes Antigens That Are Expressed on CML Progenitor CellsSemantic proximity Read ↗

Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia.Semantic proximity Read ↗

TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20+ Antibody-Secreting CellsSemantic proximity Read ↗

Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX.Semantic proximity Read ↗

Antibody-mediated pathogenesis of chronic GVHD through DBY/HLA class II complexes and induction of a GVL effectSemantic proximity Read ↗

Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy.Semantic proximity Read ↗

Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cellsSemantic proximity Read ↗

Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cellsSemantic proximity Read ↗

Antigen stimulation in the development of chronic lymphocytic leukemia.Semantic proximity Read ↗

Evaluation of the antibody response to the EBV proteome in EBV‐associated classical Hodgkin lymphomaSemantic proximity Read ↗

CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia.Semantic proximity Read ↗

Antigens recognized by autologous antibody in patients with renal-cell carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.